PCN187 BUDGET IMPACT OF SEQUENTIAL TREATMENT WITH AFATINIB FOLLOWED BY OSIMERTINIB VERSUS FIRST-LINE OSIMERTINIB IN NON-SMALL-CELL LUNG CANCER PATIENTS WITH COMMON EGFR MUTATIONS IN THE NETHERLANDS
Nov 1, 2019, 00:00
10.1016/j.jval.2019.09.383
https://www.valueinhealthjournal.com/article/S1098-3015(19)32761-5/fulltext
Title :
PCN187 BUDGET IMPACT OF SEQUENTIAL TREATMENT WITH AFATINIB FOLLOWED BY OSIMERTINIB VERSUS FIRST-LINE OSIMERTINIB IN NON-SMALL-CELL LUNG CANCER PATIENTS WITH COMMON EGFR MUTATIONS IN THE NETHERLANDS
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(19)32761-5&doi=10.1016/j.jval.2019.09.383
First page :
Section Title :
Open access? :
No
Section Order :
10315